Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report issued on Friday. The firm set a “sell” rating on the stock.

Other equities research analysts have also recently issued research reports about the company. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Price Performance

Shares of SYRS opened at $0.21 on Friday. The company has a market cap of $5.67 million, a P/E ratio of -0.07 and a beta of 1.31. Syros Pharmaceuticals has a 12 month low of $0.18 and a 12 month high of $7.96. The stock has a fifty day moving average price of $0.23 and a 200 day moving average price of $1.97.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the business posted ($1.35) earnings per share. As a group, research analysts anticipate that Syros Pharmaceuticals will post -2.94 earnings per share for the current year.

Insider Transactions at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the sale, the director now directly owns 41,070 shares in the company, valued at $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 12.26% of the stock is owned by insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

A hedge fund recently raised its stake in Syros Pharmaceuticals stock. Exome Asset Management LLC lifted its stake in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 298,575 shares of the company’s stock after purchasing an additional 139,400 shares during the period. Exome Asset Management LLC owned approximately 1.11% of Syros Pharmaceuticals worth $642,000 at the end of the most recent reporting period. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.